421 related articles for article (PubMed ID: 32064968)
1. Regulatory perspectives on next-generation sequencing and complementary diagnostics in Japan.
Shimazawa R; Ikeda M
Expert Rev Mol Diagn; 2020 Jun; 20(6):601-610. PubMed ID: 32064968
[TBL] [Abstract][Full Text] [Related]
2. Next generation sequencing in cancer: opportunities and challenges for precision cancer medicine.
Paolillo C; Londin E; Fortina P
Scand J Clin Lab Invest Suppl; 2016; 245():S84-91. PubMed ID: 27542004
[TBL] [Abstract][Full Text] [Related]
3. A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.
Dietel M; Jöhrens K; Laffert MV; Hummel M; Bläker H; Pfitzner BM; Lehmann A; Denkert C; Darb-Esfahani S; Lenze D; Heppner FL; Koch A; Sers C; Klauschen F; Anagnostopoulos I
Cancer Gene Ther; 2015 Sep; 22(9):417-30. PubMed ID: 26358176
[TBL] [Abstract][Full Text] [Related]
4. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer.
Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P
J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895
[TBL] [Abstract][Full Text] [Related]
5. Colorectal cancer molecular profiling: from IHC to NGS in search of optimal algorithm.
Furtado LV; Samowitz WS
Virchows Arch; 2017 Aug; 471(2):235-242. PubMed ID: 28551725
[TBL] [Abstract][Full Text] [Related]
6. Perspective for the development of companion diagnostics and regulatory landscape to encourage personalized medicine in Japan.
Tazawa Y
Breast Cancer; 2016 Jan; 23(1):19-23. PubMed ID: 25605056
[TBL] [Abstract][Full Text] [Related]
7. Update on molecular companion diagnostics - a future in personalized medicine beyond Sanger sequencing.
Campbell MR
Expert Rev Mol Diagn; 2020 Jun; 20(6):637-644. PubMed ID: 32167388
[TBL] [Abstract][Full Text] [Related]
8. Managing the genomic revolution in cancer diagnostics.
Nguyen D; Gocke CD
Virchows Arch; 2017 Aug; 471(2):175-194. PubMed ID: 28639053
[TBL] [Abstract][Full Text] [Related]
9. Next-Generation Sequencing and Applications to the Diagnosis and Treatment of Lung Cancer.
Kruglyak KM; Lin E; Ong FS
Adv Exp Med Biol; 2016; 890():123-36. PubMed ID: 26703802
[TBL] [Abstract][Full Text] [Related]
10. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
[TBL] [Abstract][Full Text] [Related]
11. NGS analysis on tumor tissue and cfDNA for genotype-directed therapy in metastatic NSCLC patients. Between hope and hype?
Falk AT; Heeke S; Hofman V; Lespinet V; Ribeyre C; Bordone O; Poudenx M; Otto J; Garnier G; Castelnau O; Guigay J; Leroy S; Marquette CH; Hofman P; Ilié M
Expert Rev Anticancer Ther; 2017 Aug; 17(8):681-685. PubMed ID: 28511612
[TBL] [Abstract][Full Text] [Related]
12. Review of Clinical Next-Generation Sequencing.
Yohe S; Thyagarajan B
Arch Pathol Lab Med; 2017 Nov; 141(11):1544-1557. PubMed ID: 28782984
[TBL] [Abstract][Full Text] [Related]
13. Application of next-generation sequencing in clinical oncology to advance personalized treatment of cancer.
Guan YF; Li GR; Wang RJ; Yi YT; Yang L; Jiang D; Zhang XP; Peng Y
Chin J Cancer; 2012 Oct; 31(10):463-70. PubMed ID: 22980418
[TBL] [Abstract][Full Text] [Related]
14. Comparison of next-generation sequencing and mutation-specific platforms in clinical practice.
Hinrichs JW; van Blokland WT; Moons MJ; Radersma RD; Radersma-van Loon JH; de Voijs CM; Rappel SB; Koudijs MJ; Besselink NJ; Willems SM; de Weger RA
Am J Clin Pathol; 2015 Apr; 143(4):573-8. PubMed ID: 25780010
[TBL] [Abstract][Full Text] [Related]
15. [Molecular pathology of the lungs. New perspectives by next generation sequencing].
Vollbrecht C; König K; Heukamp L; Büttner R; Odenthal M
Pathologe; 2013 Feb; 34(1):16-24. PubMed ID: 23389825
[TBL] [Abstract][Full Text] [Related]
16. Challenges and opportunities for next-generation sequencing in companion diagnostics.
Lin E; Chien J; Ong FS; Fan JB
Expert Rev Mol Diagn; 2015 Feb; 15(2):193-209. PubMed ID: 25249308
[TBL] [Abstract][Full Text] [Related]
17. Changing the Therapeutic Landscape in Non-small Cell Lung Cancers: the Evolution of Comprehensive Molecular Profiling Improves Access to Therapy.
Sabari JK; Santini F; Bergagnini I; Lai WV; Arbour KC; Drilon A
Curr Oncol Rep; 2017 Apr; 19(4):24. PubMed ID: 28303491
[TBL] [Abstract][Full Text] [Related]
18. Clinical feasibility of NGS liquid biopsy analysis in NSCLC patients.
Papadopoulou E; Tsoulos N; Tsantikidi K; Metaxa-Mariatou V; Stamou PE; Kladi-Skandali A; Kapeni E; Tsaousis G; Pentheroudakis G; Petrakis D; Lampropoulou DI; Aravantinos G; Varthalitis I; Kesisis G; Boukovinas I; Papakotoulas P; Katirtzoglou N; Athanasiadis E; Stavridi F; Christodoulou C; Koumarianou A; Eralp Y; Nasioulas G
PLoS One; 2019; 14(12):e0226853. PubMed ID: 31860648
[TBL] [Abstract][Full Text] [Related]
19. CDx, NGS and regulation: five perspectives from the Pistoia Alliance.
Wise J; Furness M; McWilliams S; Patton S
Drug Discov Today; 2019 Nov; 24(11):2120-2125. PubMed ID: 31306783
[TBL] [Abstract][Full Text] [Related]
20. Next generation sequencing in non-small cell lung cancer: new avenues toward the personalized medicine.
Coco S; Truini A; Vanni I; Dal Bello MG; Alama A; Rijavec E; Genova C; Barletta G; Sini C; Burrafato G; Biello F; Boccardo F; Grossi F
Curr Drug Targets; 2015; 16(1):47-59. PubMed ID: 25495923
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
